

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Nuedexta Clinical Edit
<b>First Implementation Date:</b>	TBD
<b>Proposed Date:</b>	September 17, 2020
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input checked="" type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** Ensure appropriate utilization and control of Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate)

**Why Issue Selected:** Nuedexta®, a combination product of dextromethorphan hydrobromide and quinidine sulfate, is the first FDA approved treatment for pseudobulbar affect (PBA). PBA is a condition that typically present in patients with neurological conditions or injuries that affect the way the brain controls emotion. The condition is characterized by episodes of sudden, uncontrollable, and inappropriate episodes of crying or laughing. PBA has a prevalence of approximately 2 million people in the United States with underlying conditions such as stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Lou Gehrig's disease (ALS), or traumatic brain injury. PBA shares several clinical features of mood disorders, however there are characteristic clinical features and validated scales to assist in determining an appropriate diagnosis and therapy. The Center for Neurologic Study – Liability Scale (CNS-LS) is a self-administered questionnaire that asks about the control of laughter and crying; this scale has been validated in patients with ALS and multiple sclerosis. The Pathological Laughter and Crying Scale (PLACS) is an interviewer administered scale assessing sudden episodes of laughter and crying; this scale has been validated in patients with acute stroke. MO HealthNet will impose clinical criteria to ensure appropriate utilization of Nuedexta therapy.

### Program-Specific Information:

Date Range FFS 7-1-2019 to 6-30-2020				
Drug	Claims	Spend	Cost per capsule	Cost per month
NUEDEXTA 20-10 MG	2,439	\$2,306,005.09	\$19.93 NADAC	\$1,195.80 NADAC

**Type of Criteria:** ☐ Increased risk of ADE  
☒ Appropriate Indications

☐ Preferred Drug List  
☒ Clinical Edit

**Data Sources:** ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate)

*SmartPA Clinical Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- Age range: All appropriate MO HealthNet participants aged 18 years or older

## Approval Criteria

### Initial Therapy:

- Participant aged 18 years or older **AND**
- Documented diagnosis of pseudobulbar affect **AND**
- Documentation of baseline episode frequency **AND**
- Participant has a Center for Neurologic Study-Lability Scale (CNS-LS) score of  $\geq 13$  **OR**
- Participant has a Pathological Laughter and Crying Scale (PLACS) score of  $\geq 13$

### Continuation of therapy:

- Initial approval is for 6 months, renewal of prior authorization may be given for up to 12 months following documentation of the following:
  - Documentation of decrease in CNS-LS score or PLACS score from baseline **AND**
  - Documentation of decrease in episode frequency from baseline

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds 2 capsules per day
- Documented history of MAOI therapy in the past 45 days
- Documented history of quinidine, quinine, or mefloquine therapy in the past 45 days

## Required Documentation

Laboratory Results:


MedWatch Form:

Progress Notes:

X
X

Other:

## Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)

Rule Type: CE

## Default Approval Period

1 year

## References

- NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.
- Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483-489. doi:10.2147/TCRM.S53906
- Genetic and Rare Diseases Information Center. Pseudobulbar affect. <https://rarediseases.info.nih.gov/diseases/12012/pseudobulbar-affect>. Accessed July 24, 2020.
- Avanir Pharmaceuticals, Inc. The Impact of PBA on Your Patients is Substantial. <https://www.nuedextahcp.com/understanding-pba>. Accessed July 24, 2020.

SmartPA Clinical Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.